FDA Approval Proof Point Not Enough To Inform Other TPD Targets

Maria Soloveychik says the approval of a bivalent degrader is an important proof point for the field, showing that these compounds can work clinically much like molecular glues. However, she cautions that one approved molecule does not necessarily validate other targets, mechanisms, or compound pharmacologies. She points to the IMiD franchise as an early example of molecular glues demonstrating the clinical power of protein degradation, and says recent advances in basic science, molecule design, and pharmacology are helping the field better understand what is needed for clinical success.